Sunho Biologics (Ticker: 2898 HK) is a Chinese  biopharmaceutical company committed to the discovery, development, and commercialization of first-in-class/best-in-class biologics that regulate the immune microenvironment by directly modulating both the innate and adaptive immune systems. Leveraging a deep understanding of immunology, Sunho has developed various types of immunotherapies, including immunocytokines, to treat cancers and autoimmune diseases. The company will list on May 24, 2024, in Hong Kong. Sunho Biologics is offering 34.15 million primary shares at the price of HKD 13.50 per share, aiming to raise HKD 461.05 million (USD 58.94 million).